<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of leptomeningeal disease from solid tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of leptomeningeal disease from solid tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of leptomeningeal disease from solid tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alexis Demopoulos, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Brown, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Leptomeningeal disease (LMD; also referred to as leptomeningeal metastases or carcinomatous meningitis) is a rare but frequently devastating complication of advanced cancer from solid tumors, most commonly lung cancer, breast cancer, and melanoma. Patients can present with a broad range of signs and symptoms due to simultaneous involvement of multiple areas of the craniospinal axis. Diagnosis often requires a high index of suspicion and is confirmed by neuroimaging and/or cerebrospinal fluid (CSF) analysis.</p><p>Patients with LMD have complex needs and are at risk for rapid deterioration. Patients often require multidisciplinary care to achieve optimal symptom control and quality of life. In addition to multifocal neurologic signs and symptoms, patients may have hydrocephalus, seizures, and dysfunction of the hypothalamic-pituitary axis.</p><p>LMD is traditionally a late-stage complication of advanced cancer with a median survival of several months. However, with improvements in systemic cancer therapies, the natural history of central nervous system (CNS) metastases is evolving, particularly for certain cancer subtypes. Prolonged survival is occasionally achieved, and selected patients with LMD have a wider range of treatment options available to them than they did previously.</p><p>The treatment of LMD from solid tumors is reviewed here. The pathophysiology, clinical manifestations, and diagnosis of LMD, and leptomeningeal involvement in hematologic malignancies, especially large cell lymphomas and acute leukemias, are discussed separately. (See  <a class="medical medical_review" href="/d/html/5185.html" rel="external">"Clinical features and diagnosis of leptomeningeal disease from solid tumors"</a> and  <a class="medical medical_review" href="/d/html/4720.html" rel="external">"Secondary central nervous system lymphoma: Clinical features and diagnosis", section on 'Leptomeningeal dissemination'</a> and  <a class="medical medical_review" href="/d/html/4521.html" rel="external">"Involvement of the central nervous system (CNS) with acute myeloid leukemia (AML)"</a>.)</p><p class="headingAnchor" id="H2622867016"><span class="h1">OVERVIEW OF APPROACH</span></p><p class="headingAnchor" id="H1671057790"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>LMD from solid tumors is usually a late-stage development associated with a prognosis of three to four months [<a href="#rid1">1-5</a>]. Patients often have widespread systemic disease, and approximately 40 percent have prior or concurrent parenchymal brain metastases [<a href="#rid5">5</a>]. Patients may succumb to LMD, progressive brain metastases, complications of systemic disease, or a combination. Nonetheless, sustained tumor control is occasionally achieved, especially in younger patients with breast cancer or oncogene-driven non-small cell lung cancer (NSCLC), as well as those with controlled systemic neoplasm and good remaining treatment options.</p><p>Tumor histology and molecular subtype are important factors influencing prognosis. In a large series of 318 patients with breast cancer and LMD, median overall survival was 3.5 months for the entire cohort [<a href="#rid6">6</a>]. Survival was longest among those with human epidermal growth factor receptor 2 (HER2)-positive disease and shortest for those with triple-negative disease (5.2 versus 2.5 months). Similarly, in NSCLC, patients with LMD from epidermal growth factor receptor (EGFR)-mutant or anaplastic lymphoma kinase (ALK)-rearranged tumors have the potential for more extended survival (eg, 12 to 18 months) compared with patients without a driver mutation [<a href="#rid7">7-12</a>]. (See <a class="local">'Patients with non-small cell lung cancer'</a> below.)</p><p>Diagnostic certainty and the radiographic pattern of LMD also impact prognosis. In a multicenter retrospective study of 254 patients with newly diagnosed solid tumor LMD, median survival was shortest in patients with confirmed LMD, defined by positive cerebrospinal fluid (CSF) cytology or biopsy (2.3 months, compared with 2.8 months for the overall cohort) [<a href="#rid5">5</a>]. Older age and non-breast histology were also associated with shorter survival. Among patients with possible or probable LMD (clinical and/or radiologic evidence but equivocal or negative cytology), those with nodular disease on imaging  (<a class="graphic graphic_diagnosticimage graphicRef132736" href="/d/graphic/132736.html" rel="external">image 1</a>) had shorter survival compared with those who had linear or absent leptomeningeal enhancement.</p><p>Identifying patients with a particularly poor prognosis can help to spare unnecessary or futile interventions and maximize supportive care and comfort  (<a class="graphic graphic_table graphicRef54352" href="/d/graphic/54352.html" rel="external">table 1</a>). Patients with a Karnofsky Performance Status (KPS) &lt;60  (<a class="graphic graphic_table graphicRef58785" href="/d/graphic/58785.html" rel="external">table 2</a>); multiple, serious, fixed neurologic deficits; untreated symptomatic hydrocephalus; or extensive systemic cancer with limited remaining therapeutic options have a poor prognosis (eg, one to two months) even with active treatment.</p><p>In the absence of these factors, the potential for sustained tumor control depends upon an individualized assessment of tumor histology and molecular subtype, extent of disease, and prior therapies. Patients with reasonable systemic treatment options, particularly agents with central nervous system (CNS) activity, do best.</p><p class="headingAnchor" id="H2"><span class="h2">Treatment plan and sequencing</span><span class="headingEndMark"> — </span>The goals of treatment in patients with LMD are to stabilize or improve neurologic function, palliate symptoms, and improve quality of life. All therapies are given with palliative intent, and certain urgent procedures, such as ventriculoperitoneal (VP) shunting for hydrocephalus, can also extend life in selected patients.</p><p>For relatively good-risk patients with a cancer for which reasonable treatment options remain, a treatment hierarchy is helpful to sequentially organize multiple required interventions  (<a class="graphic graphic_algorithm graphicRef131588" href="/d/graphic/131588.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bulky, symptomatic disease</strong> – Bulky and neurologically symptomatic areas of LMD are unlikely to respond to systemic or intrathecal (IT) therapy but often improve when treated with radiation therapy (RT). RT is typically delivered to the most symptomatic area. Radiation to the full neuroaxis (ie, craniospinal RT) utilizing <strong>protons</strong> may be considered in selected patients with better prognosis. (See <a class="local">'Radiation to symptomatic sites'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydrocephalus</strong> – A high index of suspicion for hydrocephalus is necessary in patients with LMD, as ventricles may not appear dilated, overtly obstructive disease may be absent, and symptoms may be attributed to other sites of disease. Papilledema, an opening pressure of &gt;20 cm H<sub>2</sub>O on lumbar puncture (LP), and plateau waves are clues to the diagnosis. Plateau waves are frequently confused with seizures, even by experienced clinicians. (See  <a class="medical medical_review" href="/d/html/5185.html" rel="external">"Clinical features and diagnosis of leptomeningeal disease from solid tumors", section on 'Plateau waves'</a>.)</p><p></p><p class="bulletIndent1">In some cases, urgent management of severe hydrocephalus may require delaying RT. In mild cases, RT can lead to symptom resolution and forestall or avoid shunt placement. (See <a class="local">'Hydrocephalus and increased intracranial pressure'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further CNS-directed therapy</strong> – For poor-risk patients (low KPS, widespread systemic disease without good systemic treatment options), treatment focuses upon alleviating symptoms without the use of systemic or IT anticancer therapy. For good-risk patients, selection of therapy is individualized based on extent of disease, cancer type, cancer genomics, and prior systemic treatment responsiveness.</p><p></p><p class="bulletIndent1">Control of both CNS and systemic disease may require multiple agents, although many newer therapies have demonstrated dual CNS and systemic activity. If such a treatment option exists for a patient, then we proceed with systemic therapy rather than, or in rare cases along with, IT therapy. The preference for a systemic agent is strongest for patients with active extracranial disease or concurrent parenchymal brain metastases, for whom IT therapy would not address all sites of disease. (See <a class="local">'Systemic therapy options'</a> below.)</p><p></p><p class="bulletIndent1">For patients without good systemic therapy options (eg, past adverse effects, prior lack of response, or poor reserve) who remain eligible for CNS-directed therapy (high KPS, isolated site of disease, limited extracranial disease burden), we offer IT chemotherapy. The best candidates for IT therapy are those with linear, nonbulky LMD; no hydrocephalus; and absent brain metastases. (See <a class="local">'Intrathecal therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H67775343"><span class="h2">Supportive care needs</span><span class="headingEndMark"> — </span>Intensive supportive care is important and often essential to achieve acceptable quality of life in patients with LMD. Treatment of LMD involves complex care coordination, the potential for several highly morbid complications of the disease and its treatment, and thoughtful balancing of symptom relief with the principles of self-determination.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palliative care</strong> – At each visit, a careful history and detailed neurologic evaluation should focus on frequent complications of LMD in order to anticipate palliative care needs. Cauda equina syndrome, hyponatremia, seizures, and pain require vigilance and urgent treatment. Importantly, LMD can evolve rapidly, and functional status may decline quickly in the setting of uncontrolled symptoms.</p><p></p><p class="bulletIndent1">Frequent clinical evaluations are often necessary to evaluate new symptoms, identify treatable causes, and reevaluate goals of care. Early involvement of palliative care clinicians is encouraged, whether or not a patient is pursuing disease-modifying therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain management</strong> – LMD can cause headaches, neck pain or stiffness, back pain, and radicular nerve pain. Analgesics (<a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, nonsteroidal antiinflammatory drugs, opioids) are appropriate for initial management in most cases. Glucocorticoids rarely reverse neurologic deficits from LMD but may improve headaches and radicular pain more effectively than analgesics.</p><p></p><p class="bulletIndent1">VP shunting is occasionally necessary as a palliative procedure for refractory headaches that are due to increased intracranial pressure (ICP). In patients with radicular pain, RT plays an important palliative role, especially for bulky cauda equina disease  (<a class="graphic graphic_diagnosticimage graphicRef132205" href="/d/graphic/132205.html" rel="external">image 2</a>) (see <a class="local">'Radiation to symptomatic sites'</a> below). Neuropathic agents such as <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>, and <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> can be useful as adjunctive therapies. (See  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Patients with neuropathic pain'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizures</strong> – Seizures occur in approximately one-quarter of patients with LMD. Patients who experience a seizure should be treated with an antiseizure medication indefinitely to decrease the risk of recurrent seizures. <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">Levetiracetam</a> is often a good first-line choice due to ease of administration and low potential for drug interactions [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/d/html/5181.html" rel="external">"Seizures in patients with primary and metastatic brain tumors", section on 'Approach to management'</a>.)</p><p></p><p class="bulletIndent1">Plateau waves may be mistaken for seizures and can often be recognized because they occur during positional changes. Plateau waves indicate increased ICP and will not respond to antiseizure medications. (See  <a class="medical medical_review" href="/d/html/5185.html" rel="external">"Clinical features and diagnosis of leptomeningeal disease from solid tumors", section on 'Plateau waves'</a>.)</p><p></p><p class="bulletIndent1">As in patients with brain metastases, routine prophylaxis in patients who have never had a seizure is not indicated and exposes patients to risk of side effects of antiseizure medications. (See  <a class="medical medical_review" href="/d/html/5181.html" rel="external">"Seizures in patients with primary and metastatic brain tumors", section on 'Approach to management'</a>.)</p><p></p><p class="headingAnchor" id="H2441713376"><span class="h2">Response evaluation</span><span class="headingEndMark"> — </span>Response assessment should include the triad of clinical signs and symptoms, review of neuroimaging, and CSF evaluation. Most patients will require frequent clinical assessments (eg, every two to four weeks) along with brain and spine magnetic resonance imaging (MRI) every two to three months.</p><p>The frequency of CSF evaluation depends on its ready availability. CSF can be drawn from an Ommaya or may require an LP. For those who are not receiving IT therapy, we generally coordinate CSF cytology with neuroimaging and sometimes more frequently.</p><p>For patients receiving intra-CSF therapy, we evaluate CSF for routine studies (ie, protein, glucose, cell count, Gram stain, and culture) at the time of each IT treatment and send cytology at every two to four weeks. Both ventricular and thecal CSF should be evaluated whenever possible because absence of malignant cells in one compartment (eg, ventricular) does not guarantee resolution of neoplasm in the other (eg, lumbar).</p><p>Other testing on CSF may be useful in some cases, either diagnostically or to follow response. These techniques, such as cell-free DNA analysis on CSF or measurement of tumor markers specific to a given tumor type, are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5185.html" rel="external">"Clinical features and diagnosis of leptomeningeal disease from solid tumors", section on 'Cerebrospinal fluid'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">URGENT SYMPTOMATIC INTERVENTIONS</span></p><p class="headingAnchor" id="H4285675888"><span class="h2">Radiation to symptomatic sites</span><span class="headingEndMark"> — </span>Radiation therapy (RT) should be used whenever possible to treat symptomatic areas of LMD, especially for bulky deposits in the cauda equina causing weakness, pain, or incontinence [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H82271231"><span class="h3">Involved field radiation</span><span class="headingEndMark"> — </span>The specific fields are dictated by symptoms, as reviewed below. RT frequently alleviates radicular pain and sometimes improves focal neurologic deficits such as cranial neuropathies or diffuse symptoms such as encephalopathy. It may also delay or prevent progression of neurologic deficits. By contrast, systemic therapy alone rarely reverses neurologic signs and symptoms from solid tumor LMD.</p><p>The RT plan should be individualized based on symptoms and disease distribution:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with cauda equina syndrome and/or painful radiculopathy</strong> – Lower-extremity weakness and bladder or bowel dysfunction are often seen with radiographic evidence of bulky enhancing neoplasm in the cauda equina  (<a class="graphic graphic_diagnosticimage graphicRef132204" href="/d/graphic/132204.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef132205" href="/d/graphic/132205.html" rel="external">image 2</a>). Prompt lumbosacral spine RT may recover function  (<a class="graphic graphic_diagnosticimage graphicRef132206" href="/d/graphic/132206.html" rel="external">image 4</a>). Occasionally, such symptoms occur without radiographic findings. These patients may benefit from the same palliative lumbosacral spine RT despite the absence of radiographic targets.</p><p></p><p class="bulletIndent1">For patients with painful radiculopathies above the level of the cauda equina, cervical or thoracic spine RT to the area of radiographic and clinical involvement is administered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with cranial neuropathies </strong>–<strong> </strong>Isolated cranial neuropathies may resolve with whole brain RT or limited skull base RT. The typical schedule for either whole brain RT or more limited skull base fields is 30 Gy in 10 daily fractions. Skull base RT may spare temporal lobe regions to avoid memory deficits and can sometimes be given in patients who have already received whole brain RT in the past [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with diffuse encephalopathy </strong>–<strong> </strong>Patients with diffusely symptomatic intracranial LMD are candidates for whole brain RT, especially in the presence of concurrent parenchymal brain metastases. As with other forms of RT in patients with LMD, the goal of treatment is symptom control, and overall survival may not be prolonged [<a href="#rid18">18-20</a>]. A typical schedule for whole brain RT is 30 Gy in 10 daily fractions; for poor-prognosis patients, 20 Gy in five daily fractions is sometimes used to minimize patient burden and treatment time.</p><p></p><p>Major adverse effects during or after focal RT alone are rare. With more extensive fields (eg, craniospinal or whole brain RT), major effects of RT may include myelosuppression, mucositis, esophagitis, and leukoencephalopathy. Whole brain RT can result in cognitive decline, which typically takes months or even years to become clinically apparent. However, toxicity may arise earlier when RT is given concurrently with intrathecal (IT) <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. Although many patients do not live long enough to suffer the delayed effects of RT, some do. (See  <a class="medical medical_review" href="/d/html/7053.html" rel="external">"Acute complications of cranial irradiation"</a> and  <a class="medical medical_review" href="/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation"</a>.)</p><p class="headingAnchor" id="H2527821064"><span class="h3">Proton craniospinal radiation</span><span class="headingEndMark"> — </span>Radiation to the full neuraxis (ie, craniospinal RT) with<strong> photon</strong> radiation is typically not appropriate for solid tumor LMD due to high risk of toxicity, short life expectancy, and low likelihood of meaningful benefit. However, where available, <strong>proton</strong> craniospinal RT, which has an improved toxicity profile compared with photon craniospinal RT, is an option in selected patients with adequate functional status [<a href="#rid21">21,22</a>].</p><p>In a randomized phase II trial of proton craniospinal RT versus involved field RT in 63 patients with LMD from either breast cancer or non-small cell lung cancer (NSCLC), proton craniospinal RT improved both median central nervous system (CNS) progression-free survival (7.5 versus 2.3 months) and overall survival (9.9 versus 6.0 months) compared with involved field RT, with no difference in the rate of serious adverse effects [<a href="#rid22">22</a>]. Approximately one-half of patients in each group had active systemic disease at the time of enrollment, and nearly one-half in each group had a targetable variant (eg, <em>HER2</em>, epidermal growth factor receptor [<em>EGFR</em>]). In an exploratory cohort of 35 patients with other histologies treated with proton craniospinal RT, median CNS progression-free and overall survival were 5.8 and 6.6 months, respectively, and there were more systemic disease progression-related deaths compared with the breast and NSCLC patients.</p><p class="headingAnchor" id="H1487052850"><span class="h2">Hydrocephalus and increased intracranial pressure</span><span class="headingEndMark"> — </span>Hydrocephalus and increased intracranial pressure (ICP), even without ventriculomegaly, are significant causes of intractable headache, cognitive slowing, gait abnormalities, and incontinence in patients with LMD. Hydrocephalus from LMD is a subacute process, and symptoms usually evolve over the course of weeks rather than days. With a high index of suspicion and early recognition, decisions about shunting can often be made in the outpatient setting.</p><p>Patients with LMD may have either communicating or noncommunicating hydrocephalus, and treatment approaches vary depending on the type.</p><p class="bulletIndent1"><span class="glyph">●</span>In <strong>communicating hydrocephalus</strong> from LMD, the ventricles are symmetrically dilated above and below the third ventricle without focal sites of obstruction. The mechanism is thought to be an interruption of cerebrospinal fluid (CSF) resorption by malignant cell clumping at the level of the arachnoid granulations, which in most cases is microscopic and not visible on magnetic resonance imaging (MRI)  (<a class="graphic graphic_diagnosticimage graphicRef132204" href="/d/graphic/132204.html" rel="external">image 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less commonly in LMD, <strong>noncommunicating </strong>(obstructive) <strong>hydrocephalus</strong> occurs due to bulky parenchymal or leptomeningeal tumors obstructing the cerebral aqueduct, fourth ventricle, or spinal canal. CSF flow studies occasionally identify an otherwise radiographically occult regional block that may be a target for focal RT [<a href="#rid23">23</a>]. Rarely, hydrocephalus may occur without intracranial disease in the setting of nodular spinal cord deposits and respond to focal RT to the spine.</p><p></p><p class="headingAnchor" id="H2478798944"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>A trial of glucocorticoids is appropriate for patients with symptoms of elevated ICP from LMD, although steroids are not a definitive treatment for hydrocephalus. Nonetheless, some patients will respond symptomatically with a decrease in headaches.</p><p>A typical starting dose is <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 8 to 16 mg per day in one or two divided doses. Maximal clinical response should occur within two to three days of starting steroids. A taper can then be attempted, aiming for the lowest effective dose necessary to control symptoms. (See  <a class="medical medical_review" href="/d/html/5182.html" rel="external">"Management of vasogenic edema in patients with primary and metastatic brain tumors", section on 'Symptomatic treatment'</a>.)</p><p>For patients with frank hydrocephalus on imaging, glucocorticoids are less likely to improve symptoms and are generally only a temporizing measure until definitive treatment with CSF diversion or RT.</p><p class="headingAnchor" id="H3342496665"><span class="h3">Lumbar puncture</span><span class="headingEndMark"> — </span>Because most LMD-related hydrocephalus is communicating and arises without an overtly obstructive mass lesion, urgent lumbar puncture (LP) typically resolves hydrocephalus temporarily without risk for herniation. LP then allows time for further management and provides CSF for analysis and opening pressure measurement. Although CSF is produced at a rate of 20 mL/hour, relief of symptomatic hydrocephalus typically lasts for days.</p><p class="headingAnchor" id="H755628927"><span class="h3">Shunting versus radiation therapy</span><span class="headingEndMark"> — </span>In patients for whom further disease-modifying therapy is planned, hydrocephalus from LMD requires either CSF diversion via ventriculoperitoneal (VP) shunting or RT. Systemic and IT therapy alone do not address hydrocephalus.</p><p>The appropriate therapy depends on the severity of hydrocephalus and the type (communicating or noncommunicating).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe hydrocephalus</strong> – Patients with severe hydrocephalus of either type require a VP shunt for relief of symptoms, even if symptoms improve with steroids, pain medications, and antiemetics. Although overall survival may not be improved by CSF diversion, shunting commonly relieves suffering and improves quality of life. (See <a class="local">'Ventriculoperitoneal shunting'</a> below.)</p><p></p><p class="bulletIndent1">Decisions about a surgical intervention in patients with a terminal condition such as LMD should include patients' known wishes, caregiver input, and ethical considerations governing end-of-life care [<a href="#rid24">24</a>]. Hydrocephalus causes cognitive deficits, gait impairment, incontinence, and symptoms of increased ICP such as headache and intractable nausea and vomiting. While not all of these symptoms will improve following CSF diversion, none will improve without intervention. (See  <a class="medical medical_review" href="/d/html/2202.html" rel="external">"Ethical issues in palliative care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less severe, communicating hydrocephalus</strong> – For patients with milder degrees of communicating hydrocephalus, and for those with nonspecific symptoms that may or may not be the result of hydrocephalus, an LP with measurement of opening pressure is often useful as an initial diagnostic and therapeutic procedure. A therapeutic response to high-volume LP (eg, removal of greater than 20 mL of CSF) offers reasonable assurance that VP shunting will provide palliative benefit. (See <a class="local">'Ventriculoperitoneal shunting'</a> below.)</p><p></p><p class="bulletIndent1">For patients who undergo LP and respond with a decrease in headaches or other symptoms, we typically offer VP shunting. In patients who do not respond clinically to high-volume LP, or for those who prefer to avoid a surgical procedure, whole brain or skull base RT may forestall and sometimes resolve hydrocephalus and elevated ICP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less severe, noncommunicating (obstructive) hydrocephalus</strong> – Unlike patients with communicating hydrocephalus, patients with obstructive hydrocephalus are at risk for herniation with removal of lumbar CSF and should not undergo LP. RT to the site of obstruction may be reasonable in patients who are asymptomatic and can be observed closely for signs of deterioration. However, we have a low threshold for VP shunting, as obstructive tumors may rapidly recur after an initial positive response to RT.</p><p></p><p class="headingAnchor" id="H2811347927"><span class="h3">Ventriculoperitoneal shunting</span><span class="headingEndMark"> — </span>VP shunting is a relatively safe and effective way to relieve hydrocephalus and refractory symptoms of elevated ICP in patients with LMD [<a href="#rid25">25-29</a>].</p><p>VP shunting is usually performed in the presence of frank hydrocephalus, with dilated ventricles and evidence of transependymal flow of CSF on MRI  (<a class="graphic graphic_diagnosticimage graphicRef87728" href="/d/graphic/87728.html" rel="external">image 5</a>). However, in some cases, a communicating hydrocephalus from LMD can cause elevated ICP without significantly increasing the size of the ventricles. Such patients are also candidates for VP shunting to relieve refractory headaches or other symptoms of ICP as documented by an increased opening pressure (&gt;20 cm H<sub>2</sub>0). However, the surgical procedure may be more difficult because the ventricles are relatively small.</p><p>Outcomes associated with VP shunting are illustrated by a meta-analysis that identified 10 retrospective studies in a total of 420 patients undergoing shunting for LMD from solid tumors, mostly lung and breast malignancies [<a href="#rid30">30</a>]. Overall survival ranged from two to three months after shunt placement. Symptom relief was usually seen (67 to 100 percent) with higher improvement rates for headaches, nausea, and confusion than for focal neurologic deficits and cranial nerve palsies. Among 109 patients in four studies reporting pre- and postoperative Karnofsky performance status (KPS), a mean KPS improvement of 16.7 points was seen. Overall complication rates ranged from 10 to 20 percent. The most frequent complications were mechanical shunt failure (8.6 percent), overdrainage and other manifestations of functional failure (5 percent), and infection (3.8 percent). Approximately half the patients suffering a complication required an additional surgical procedure. Only one case of peritoneal metastasis after surgery was identified, and the authors attributed it to systemic cancer progression, not the VP shunting. Intestinal perforation was identified in 36 patients (8.6 percent). Separately, peritoneal spread of germinoma, sarcoma, medulloblastoma, and glioblastoma with primitive neuroectodermal features has been reported in children [<a href="#rid31">31,32</a>] but almost never occurs in adult patients [<a href="#rid24">24,33</a>].</p><p>Of note, standard VP shunt placement will divert IT therapy from intracranial tumor into the abdominal cavity. Several investigators have used programmable VP shunts or on/off valves to deliver chemotherapy, stop CSF outflow in order to expose leptomeningeal tumor to the drug, and then reopen CSF diversion 24 hours later to treat hydrocephalus [<a href="#rid34">34,35</a>]. The effectiveness of IT therapy delivered by this method has not been established and the risk of toxicity may be higher, since the injected agent remains in the ventricular system and diffuses into the surrounding brain, increasing potential toxicity, until the valve is opened. In one study, such modified shunts appeared as effective as administering chemotherapy through an intraventricular access device in the absence of hydrocephalus [<a href="#rid35">35</a>], but in another study, 17 of 70 shunted patients required shunt revision due to malfunction or infection [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H3955653906"><span class="h1">SYSTEMIC THERAPY OPTIONS</span><span class="headingEndMark"> — </span>A growing number of anticancer therapies, especially molecularly targeted drugs and immunotherapies, penetrate into the central nervous system (CNS) and have some reported utility in patients with LMD.</p><p>Systemic therapy in patients with LMD is individualized. There is no single drug with guaranteed activity across multiple different histologies. In general, we choose an agent (chemotherapy, targeted therapy, or immunotherapy) with the highest likelihood of both CNS penetration and efficacy against the primary cancer.</p><p>The options are organized below by primary cancer type, although for some therapies, such as immunotherapy and therapies targeting a common genetic mutation, patients with multiple cancer types may be eligible for the same agent. Should disease progress on one targeted agent, responses are sometimes achieved using an alternative medication targeting the same mutation.</p><p class="headingAnchor" id="H1891842729"><span class="h2">Patients with breast cancer</span><span class="headingEndMark"> — </span>Patients with LMD from breast cancer are considered similarly to those with parenchymal brain metastases in terms of systemic therapy options, where a choice of systemic therapy is guided by response to prior therapies, the hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, programmed death ligand 1 (PD-L1) expression, and other susceptibility gene mutations found in the tumor.</p><p>For HER2-positive disease, several agents or combinations have sufficient CNS penetration to be considered for use in patients with LMD following radiation therapy (RT) to symptomatic sites of disease and control of hydrocephalus if present. Frequently, brain metastases are HER2-positive, even in the setting of HER2-negative extracranial disease [<a href="#rid36">36</a>]. In the DEBRAH prospective study, intracranial responses to HER2-directed therapies occurred later than systemic responses (median time to response for intracranial and extracranial disease was 3.4 versus 1.3 months, respectively) [<a href="#rid37">37</a>].</p><p>A paucity of data remains regarding chemotherapeutic options for patients with LMD despite ongoing investigations, but rationale for their use may be extrapolated from treatment of patients with active brain metastases, reviewed in detail elsewhere. Examples of demonstrably CNS active regimens include trastuzumab-emtansine (T-DM1), <a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> [T-DXd], <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> alone, <a class="drug drug_general" data-topicid="127946" href="/d/drug information/127946.html" rel="external">tucatinib</a> in combination with capecitabine and <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>, and capecitabine with <a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">lapatinib</a> or <a class="drug drug_general" data-topicid="114008" href="/d/drug information/114008.html" rel="external">neratinib</a>. The ongoing ROSET-BM trial of T-DXd reported one-year progression-free survival of 61 percent and one-year overall survival of 87 percent among 19 patients with LMD, of whom 17 had concurrent brain metastases [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/775.html" rel="external">"Brain metastases in breast cancer", section on 'HER2-positive disease'</a>.)</p><p>Absent a targeted therapy option, we consider use of either high-dose intravenous <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or single-agent <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-dose </strong><strong>methotrexate</strong> – Systemic administration of high-dose intravenous <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> with <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> rescue is an alternative to intrathecal (IT) methotrexate administration in patients who cannot receive IT therapy. Although studies assessing the effectiveness of high-dose methotrexate in patients with LMD from solid tumors are mixed [<a href="#rid39">39-44</a>], clinical experience supports a beneficial role in selected patients with breast cancer LMD.</p><p></p><p class="bulletIndent1">Most studies have used a dose of 3 to 3.5 g/m<sup>2</sup> given every two weeks. In the two larger series composed primarily of patients with LMD from breast cancer, the rate of stable disease ranged from 30 to 45 percent, with no complete responses and median survival of five to six months [<a href="#rid40">40,41</a>]. More prolonged survival has been described mostly in case reports [<a href="#rid41">41-43</a>].</p><p></p><p class="bulletIndent1">Although ambulatory regimens are under investigation [<a href="#rid45">45</a>], high-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> presently requires hospitalization for hydration, urinary alkalinization, and <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> rescue at a center experienced with the regimen to avoid systemic methotrexate toxicity. If patients develop early renal insufficiency and plasma methotrexate levels remain high for a prolonged period despite these measures, early treatment with <a class="drug drug_general" data-topicid="9048" href="/d/drug information/9048.html" rel="external">glucarpidase</a> (carboxypeptidase G2 [CPDG2]) to metabolize the methotrexate is crucial to preventing severe toxicity and death. The use of high-dose methotrexate and crystal-induced renal failure in patients treated with methotrexate are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Alternative rescue techniques for patients with renal failure'</a> and  <a class="medical medical_review" href="/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Capecitabine</strong> – <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a>, an oral prodrug of <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, has induced responses and disease stabilization in some patients with LMD from breast and other solid tumors [<a href="#rid46">46-50</a>]. Some responses continued for more than 12 months [<a href="#rid49">49,51</a>].</p><p></p><p class="headingAnchor" id="H811983307"><span class="h2">Patients with non-small cell lung cancer</span><span class="headingEndMark"> — </span>Systemic administration of genotype-directed targeted therapies can result in clinical benefit in appropriately selected patients with non-small cell lung cancer (NSCLC) with CNS disease, including LMD.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidermal growth factor receptor (EGFR)-mutant NSCLC </strong>– The EGFR tyrosine kinase inhibitors have CNS activity in patients with EGFR-mutant NSCLC. Most data are in patients with brain metastases and are reviewed separately. (See  <a class="medical medical_review" href="/d/html/114697.html" rel="external">"Brain metastases in non-small cell lung cancer", section on 'Patients with oncogenic drivers'</a>.)</p><p></p><p class="bulletIndent1">Available data in patients with LMD include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Osimertinib</strong> – <a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">Osimertinib</a> is a third-generation EGFR inhibitor with significant intracranial activity. In a multicenter phase I trial of double-dose osimertinib (160 mg) in patients with LMD from EGFR-mutant lung cancer that had progressed on prior EGFR targeted therapy, 17 of 41 enrolled patients (41 percent) were alive and progression free at 12 months [<a href="#rid7">7</a>]. Recurrences were seen more often outside the CNS, and drug dose reduction, discontinuation, and interruption were observed in 5, 9, and 24 patients, respectively. Other studies have confirmed activity with osimertinib 80 mg daily, including a study of 22 EGFR T790M-positive patients with LMD in which 52 percent of patients were alive at 18 months [<a href="#rid8">8,52</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Afatinib</strong> – <a class="drug drug_general" data-topicid="90144" href="/d/drug information/90144.html" rel="external">Afatinib</a> is a second-generation drug that has activity in patients with LMD from EGFR-mutant NSCLC [<a href="#rid53">53-56</a>]. Multiple case reports describe responses in afatinib-naïve patents, including at least one report of a patient with LMD responding to afatinib after progression on <a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">osimertinib</a> [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gefitinib</strong><strong> and </strong><strong>erlotinib</strong><strong> </strong>– In case reports, patients with LMD from lung adenocarcinoma improved clinically and radiographically after treatment with standard-dose [<a href="#rid57">57-60</a>] or high-dose [<a href="#rid61">61,62</a>] <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a>. Two reports observed a good response using <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> at a higher dose (either 600 mg daily or 1500 mg once weekly) [<a href="#rid63">63,64</a>]. Occasional responses to higher-dose erlotinib following failure with standard-dose regimens have also been described [<a href="#rid65">65,66</a>].</p><p></p><p class="bulletIndent2">In a single-center study involving 22 EGFR-mutant lung adenocarcinoma patients with LMD, erlotinib-treated patients had a longer overall survival than gefitinib-treated patients (6.6 versus 2.1 months, respectively) [<a href="#rid67">67</a>]. Rechallenge with a second EGFR tyrosine kinase inhibitor led to improved survival in one study of 92 EGFR-mutant lung cancer patients with LMD after progression on the first drug; overall survival in patients rechallenged with a tyrosine kinase inhibitor was 7.6 months compared with 4.2 months without rechallenge [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anaplastic lymphoma kinase (ALK)-rearranged NSCLC </strong>– ALK inhibitors <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a>, <a class="drug drug_general" data-topicid="95046" href="/d/drug information/95046.html" rel="external">ceritinib</a>, <a class="drug drug_general" data-topicid="105868" href="/d/drug information/105868.html" rel="external">alectinib</a>, <a class="drug drug_general" data-topicid="112993" href="/d/drug information/112993.html" rel="external">brigatinib</a>, and <a class="drug drug_general" data-topicid="119539" href="/d/drug information/119539.html" rel="external">lorlatinib</a> have activity in patients with ALK fusion oncogene-positive NSCLC. The reported prevalence of ALK rearrangements in unselected NSCLC is approximately 4 percent. Up to 40 percent of patients with ALK-positive lung cancer will have CNS spread at diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lorlatinib</strong> – <a class="drug drug_general" data-topicid="119539" href="/d/drug information/119539.html" rel="external">Lorlatinib</a> is a third-generation ALK inhibitor with high CNS penetration and intracranial activity in treatment-naïve as well as pretreated ALK-positive NSCLC. Lorlatinib was active in two patients with LMD in one report, including one patient with a complete and ongoing response at 22 months [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Second-generation drugs</strong> – <a class="drug drug_general" data-topicid="105868" href="/d/drug information/105868.html" rel="external">Alectinib</a>, <a class="drug drug_general" data-topicid="112993" href="/d/drug information/112993.html" rel="external">brigatinib</a>, and <a class="drug drug_general" data-topicid="95046" href="/d/drug information/95046.html" rel="external">ceritinib</a> have important clinical activity in patients with brain metastases, including those with LMD.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a phase I dose-escalation study of <a class="drug drug_general" data-topicid="105868" href="/d/drug information/105868.html" rel="external">alectinib</a>, 21 patients had CNS metastases at baseline, of whom 52 percent achieved an objective response, including 29 percent with complete responses [<a href="#rid70">70</a>]. Only two patients (10 percent) had radiographic progression.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>As with the EGFR inhibitors, switching from one ALK inhibitor to another has shown efficacy in several LMD case reports [<a href="#rid9">9-11</a>]. Dose escalation can also prove effective [<a href="#rid12">12</a>]. One case report described a durable (&gt;15 month) clinical and radiographic response to <a class="drug drug_general" data-topicid="105868" href="/d/drug information/105868.html" rel="external">alectinib</a> after symptomatic LMD developed on <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a> [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In early trials, measurable reduction in brain metastases was seen with <a class="drug drug_general" data-topicid="112993" href="/d/drug information/112993.html" rel="external">brigatinib</a> therapy in patients previously treated with <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a> and in ALK inhibitor-naïve patients. CNS progression-free survivals exceed 14 months on this therapy with modestly improved outcomes on 180 mg/day over 90 mg/day [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Crizotinib</strong> – <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">Crizotinib</a> is a first-generation ALK inhibitor with modest CNS activity compared with later-generation drugs. In a pooled retrospective analysis of patients with asymptomatic brain metastases from ALK-rearranged NSCLC enrolled in two clinical trials of crizotinib, intracranial disease control rates were similar to rates of systemic disease control [<a href="#rid74">74</a>]. Such responses tend not to be durable, however.</p><p></p><p class="headingAnchor" id="H1669212028"><span class="h2">Patients with melanoma</span><span class="headingEndMark"> — </span>Despite significant progress in melanoma therapeutics, the prognosis of patients with LMD remains quite limited, and treatment decisions must be individualized [<a href="#rid75">75,76</a>]. In a retrospective study of 52 patients with melanoma and LMD diagnosed between 2011 and 2019, the median overall survival was 2.9 months. Most patients received either targeted therapy or immunotherapy; however, among patients who received systemic therapy, overall survival was only slightly longer (3.7 months).</p><p>In BRAF-mutant melanoma patients, case reports describe durable responses to <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> and <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> in several patients with LMD [<a href="#rid77">77-82</a>].</p><p>In an early case series of 39 melanoma LMD patients, treatment with targeted agents and/or immunotherapies led to longer survivals compared with untreated patients. Median overall survival was 16.4 weeks, and 3 of 25 (12 percent) treated patients were alive at one year (range 2 to 235.1 weeks) [<a href="#rid83">83</a>]. A randomized phase II trial of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in 79 melanoma patients with brain metastases demonstrated intracranial responses to therapy [<a href="#rid84">84</a>].</p><p>Prolonged survival after checkpoint inhibitor therapy (<a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, or <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>) in patients with LMD from melanoma has also been described [<a href="#rid85">85,86</a>]. Checkpoint therapy-naïve patients may have better response to these agents [<a href="#rid87">87-89</a>], which have shown efficacy in patients with primary leptomeningeal melanomatosis as well [<a href="#rid90">90,91</a>]. (See  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma", section on 'Systemic therapy'</a>.)</p><p class="headingAnchor" id="H3102291684"><span class="h2">Other tumor types</span><span class="headingEndMark"> — </span>Patients with LMD related to a less common primary tumor type, such as ovarian cancer, colon cancer, gastric cancer, renal cell carcinoma, are often heavily pretreated and have limited systemic chemotherapy options. Such patients often have limited overall survival, and RT to symptomatic areas plays a primary role in palliation.</p><p>For patients who have a good functional status and are candidates for further systemic therapy, agents are generally selected based knowledge of CNS penetration. Drugs that have reasonable CNS penetration and activity against some solid tumors include <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> and nitrosoureas (gliomas), <a class="drug drug_general" data-topicid="10007" href="/d/drug information/10007.html" rel="external">topotecan</a> (ovarian, small cell lung cancer), <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (colon, pancreatic cancer), and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> (ovarian, lung cancer) [<a href="#rid92">92-94</a>]. IT chemotherapy may also be an option in some of these patients. (See <a class="local">'Intrathecal therapy'</a> below.)</p><p class="headingAnchor" id="H3125563843"><span class="h2">Role of immunotherapy</span><span class="headingEndMark"> — </span>For patients who are immunotherapy naïve with a range of histologies, checkpoint inhibitors have some evidence of activity in LMD, although median survival in prospective studies of patients with LMD has been modest. Glucocorticoids are typically tapered as low as possible to maximize responsiveness to immunotherapy. In a review of case reports and retrospective series that included 61 patients with LMD from a variety of neoplasms treated with checkpoint inhibitors, 12-month survival was 32 percent, highlighting occasional successes [<a href="#rid95">95</a>].</p><p><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> induced dramatic, durable, and prolonged responses in two patients with LMD due to lung cancer and in one patient with renal cell cancer LMD, with ongoing disease-free survivals of three, four, and three years at publication [<a href="#rid96">96-98</a>]. Long-term survival has also been reported in melanoma after multimodal therapy that included immunotherapy [<a href="#rid88">88</a>]. In a single-arm phase II study of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in 20 patients with solid tumor LMD (17 patients with breast cancer, 2 with lung cancer, and 1 with ovarian cancer), approximately 50 percent of patients achieved stable disease and 60 percent were alive at three months [<a href="#rid99">99</a>]. The median overall survival remained limited at 3.6 months.</p><p>Combination therapy has also been studied. In a phase II study of <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> plus <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> in 18 patients with LMD from breast cancer (n = 8) and a range of other solid tumor histologies, 39 percent had stable disease in the CNS as a best response, and there was one complete response; median overall survival was 2.9 months [<a href="#rid100">100</a>]. The rate of grade 3/4 toxicities was 33 percent, and two patients discontinued therapy due to toxicity (colitis and hepatitis).</p><p class="headingAnchor" id="H661357207"><span class="h1">INTRATHECAL THERAPY</span><span class="headingEndMark"> — </span>Intrathecal (IT) chemotherapy has historically been a primary therapy for LMD in patients with solid tumors, although its efficacy is modest and its superiority compared with systemic treatment has not been established in randomized trials [<a href="#rid101">101</a>]. As discussed above, we generally favor systemic therapy over IT therapy for patients who have a reasonable systemic option  (<a class="graphic graphic_algorithm graphicRef131588" href="/d/graphic/131588.html" rel="external">algorithm 1</a>). (See <a class="local">'Treatment plan and sequencing'</a> above.)</p><p>The drugs most commonly used for IT chemotherapy in patients with solid tumor LMD are <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9992" href="/d/drug information/9992.html" rel="external">thiotepa</a>, and <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>. Methotrexate is preferred in patients with breast cancer and is a reasonable first-line choice for IT therapy in other solid tumor types as well.</p><p class="headingAnchor" id="H3705959776"><span class="h2">Candidates for IT therapy</span><span class="headingEndMark"> — </span>The best candidates for IT therapy are those without bulky LMD, with no hydrocephalus, and with absent parenchymal brain metastases [<a href="#rid16">16</a>]. The presence of hydrocephalus, even when mild or asymptomatic, is a sign that cerebrospinal fluid (CSF) flow dynamics are abnormal, and the risk of toxicity from administration of IT chemotherapy is increased. A minority of centers use a pretreatment CSF flow study to further investigate CSF flow dynamics before treating with IT therapy. (See <a class="local">'Pretreatment CSF flow study'</a> below.)</p><p>IT chemotherapy is more likely to be effective for small leptomeningeal deposits and individual tumor cells floating in the CSF [<a href="#rid102">102,103</a>]. It cannot reliably treat bulky disease, because diffusion of drug into tumor deposits thicker than 1 to 3 mm is limited. IT chemotherapy does not treat dural-based disease or parenchymal disease.</p><p class="headingAnchor" id="H697816370"><span class="h2">Pretreatment CSF flow study</span><span class="headingEndMark"> — </span>Prior to radiation therapy (RT) or IT chemotherapy, a CSF flow study via a radionuclide cisternogram may be helpful although not available or used in all centers. This study will identify areas of obstruction that will prevent the chemotherapy from being homogeneously distributed, potentially decreasing efficacy and increasing toxicity. As an example, the administration of intraventricular <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> through an Ommaya reservoir can cause leukoencephalopathy even at conventional doses if there is a block to egress of the drug from the ventricular system. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Leukoencephalopathy'</a>.)</p><p>Abnormal CSF flow is seen in up to two-thirds of patients with LMD, often without evidence of hydrocephalus or other abnormalities on conventional neuroimaging studies [<a href="#rid104">104-106</a>]. Common sites of obstructed CSF flow include the base of the brain (ventricular outlet obstruction), within the spinal canal at the thoracic level, and over the cortical convexities. For centers that obtain CSF flow studies, RT can be delivered to areas of obstruction, even though no lesion is identified by magnetic resonance imaging (MRI), as it can restore CSF flow. A flow study is then repeated after RT to determine eligibility for IT chemotherapy.</p><p class="headingAnchor" id="H1806044841"><span class="h2">Route of administration</span><span class="headingEndMark"> — </span>IT chemotherapy involves the injection of antitumor agents into the CSF, either directly into the lateral ventricle through a subcutaneous reservoir and ventricular catheter (ie, an Ommaya device) or into the lumbar thecal sac by lumbar puncture (LP). If an Ommaya is placed, it is important to check for correct placement before chemotherapy is initiated, as administration of drug into the brain parenchyma may cause focal parenchymal injury.</p><p>Whenever possible, we suggest that IT chemotherapy be administered through a subcutaneous reservoir and ventricular catheter directly into the lateral ventricle (eg, an Ommaya device), rather than by LP [<a href="#rid16">16</a>]. Ventricular administration generally results in better distribution and avoids the approximately 10 percent risk that lumbar injections do not enter the CSF space [<a href="#rid107">107,108</a>]. Repeat LP is required in patients who unable or unwilling to undergo surgical placement of a reservoir.</p><p>Ommaya access is possible at lower platelet levels, so drug may be delivered in the setting of chemotherapy-induced thrombocytopenia. An Ommaya reservoir may be accessed with a platelet count as low as 20,000/microL, although special precautions are necessary, such as gently handling the syringe and taking care not to exert too much force in withdrawing fluid. However, administering <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> if the platelet count is below 50,000/microL is <strong>not </strong>recommended. (See <a class="local">'Methotrexate'</a> below.)</p><p>Limited data suggest that the complication rate of intraventricular reservoirs is low in patients with LMD from solid tumors [<a href="#rid109">109,110</a>]. In a single-center prospective study of 112 such patients treated with a mean of nine intraventricular chemotherapy injections each (mostly liposomal cytarabine), the overall catheter-related complication rate was 10 percent [<a href="#rid109">109</a>]. There were seven infections; of these, three occurred within 30 days of surgery and four were likely related to access of the reservoir for chemotherapy injection. All affected patients presented with a febrile meningeal syndrome, and bacterial meningitis was confirmed in the majority; one case was fatal.</p><p class="headingAnchor" id="H146946808"><span class="h2">Technique of administration</span><span class="headingEndMark"> — </span>Careful attention to minimizing any change in CSF volume with IT therapy is critical. Serious complications (eg, headache, nausea and vomiting, obtundation, herniation) can develop acutely if the total volume is increased even in asymptomatic patients with LMD, because they may be on the edge of their CSF ventricular compliance ("pressure-volume") curve. Thus, equivalent volumes of CSF (usually 7 to 10 mL) should be removed prior to instilling IT chemotherapy.</p><p>Conversely, decreases in CSF volume can cause patients to develop a pressure sensation (usually frontal or retroorbital) during the withdrawal of large volumes of CSF from the ventricles. This sensation disappears promptly after fluid is replaced during the chemotherapy infusion and is less common if the procedure is performed with the patient supine.</p><p>Administration of intraventricular chemotherapy follows a standard procedure  (<a class="graphic graphic_movie graphicRef91667" href="/d/graphic/91667.html" rel="external">movie 1</a>). After sterile preparation of the skin with <a class="drug drug_general" data-topicid="9801" href="/d/drug information/9801.html" rel="external">povidone iodine</a>, a 23-gauge butterfly needle attached to a three-way stopcock is inserted into the ventricular reservoir. Approximately 15 to 20 mL of CSF are then withdrawn gradually over two to five minutes (depending upon patient tolerance) into syringes no larger than 10 mL. Syringes should be partially opened and closed prior to their attachment to the stopcock. The first 10 mL syringe is left attached to the stopcock and is used to flush the chemotherapy through the butterfly needle and Ommaya catheter following drug administration. The remaining CSF is sent for cytology and other studies.</p><p>Once the CSF has been withdrawn, the syringe containing the drug is attached to a stopcock port. The port pointing to the ceiling is best, to avoid injecting air into the ventricle. A small amount of CSF is withdrawn into the syringe to ensure continued correct placement of the butterfly needle. The chemotherapy is then administered slowly, generally over two to three minutes. In some patients, particularly those with small ventricles or elevated intracranial pressure (ICP), a slower rate of administration is necessary to avoid headache.</p><p>CSF from the original 10 mL syringe is then drawn into the chemotherapy syringe by repositioning the stopcock and is subsequently injected through the reservoir over two to three minutes, in order to flush any drug remaining through the chemotherapy syringe or reservoir into the ventricular system in a sterile fashion. The needle is then removed, and light pressure is applied with a sterile gauze pad.</p><p>The use of IT <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> (15 to 30 mg) in conjunction with IT chemotherapy was popularized in the 1970s and thought to reduce toxicity [<a href="#rid111">111</a>]. However, there are no controlled trials proving benefit, and most investigators do not use IT glucocorticoids for patients with solid tumor LMD receiving water-soluble <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, or other IT chemotherapy. IT hydrocortisone can itself cause a chemical meningitis and should be avoided.</p><p class="headingAnchor" id="H2208370270"><span class="h2">Specific agents</span></p><p class="headingAnchor" id="H15"><span class="h3">Methotrexate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> is the chemotherapeutic agent most commonly used for IT therapy in LMD. It has activity against breast cancer and hematologic malignancies but is less active against other solid tumors such as lung cancer and sarcoma. In the CSF, methotrexate has a half-life of 4.5 hours, declining to subtherapeutic levels within four days.</p><p>In small prospective series of IT <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> in patients with mostly solid tumor LMD, the cytologic response rate ranges from 20 to 61 percent, with few or no patients showing neurologic improvement or recovery of function [<a href="#rid2">2,39,112</a>]. The experience with IT methotrexate in conjunction with RT is illustrated by several retrospective series [<a href="#rid113">113-115</a>]. In one report, median survival ranged from three months in patients with breast cancer to eight months in those with lymphoma, although responding patients occasionally survived substantially longer [<a href="#rid113">113</a>]. In another series, patients who responded to treatment by the end of one month exhibited a median additional survival of six months, while those not responding survived an additional two months [<a href="#rid114">114</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – A standard induction regimen consists of a fixed dose of 10 or 12 mg twice a week for four weeks or until cytology becomes negative for malignant cells. For IT use, preservative-free <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> is diluted to a concentration of up to 4 mg/mL in an appropriate sterile, preservative-free medium such as 0.9 percent sodium chloride injection.</p><p></p><p class="bulletIndent1">To minimize the risk of systemic <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> toxicity, we routinely give concurrent oral <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (10 mg twice daily for three days) to all patients to minimize myelosuppression related to methotrexate leaving the CSF and entering the bloodstream before being eliminated by the kidneys. Leucovorin does not cross the blood-brain barrier and does not affect the activity of methotrexate against LMD. Thus, it may be started at the same time as the IT methotrexate.</p><p></p><p class="bulletIndent1">If no cytologic response to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> is seen after four weeks, therapeutic options include another four weeks of induction therapy or a trial with an alternative agent. If clinical response occurs, the frequency of administration is decreased to weekly for four to eight weeks, and then a maintenance regimen is continued with drug administration every two weeks for several months, and then monthly for two to four months. The optimal duration of therapy in responding patients is uncertain; however, treatment beyond six months may be unnecessary [<a href="#rid112">112</a>]. (See <a class="local">'Response evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Continuous exposure to low systemic concentrations of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> can cause severe myelosuppression. Methotrexate is not metabolized in the CSF. It is absorbed slowly by the choroid plexus [<a href="#rid116">116</a>], released into the systemic circulation, and then excreted by the kidneys.</p><p></p><p class="bulletIndent1">The risk of serious myelosuppression is increased in patients with one or more of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal insufficiency, resulting in delayed excretion of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pleural effusion or ascites, which can accumulate <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and then slowly release drug into the systemic circulation (the "third space" effect)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal CSF flow, prolonging release of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> from the CSF into the systemic circulation</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> is partially bound to serum albumin. Thus, toxicity can be increased when drugs that displace methotrexate from albumin are coadministered (eg, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, sulfonamides, and <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>).</p><p></p><p class="bulletIndent1">We do not administer <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> to patients with a platelet count ≤50,000/microL. If the platelet count is between 50,000 and 150,000/microL, we give concurrent oral <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (10 mg four times daily for three days). Leucovorin does not cross the blood-brain barrier but will counteract systemic methotrexate effects on the bone marrow and gastrointestinal epithelium. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Rationale for leucovorin rescue'</a>.)</p><p></p><p class="bulletIndent1">A variety of neurologic complications can result from IT <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> therapy. These include chemical (aseptic) meningitis, delayed leukoencephalopathy, acute encephalopathy, and transverse myelopathy. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Methotrexate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Accidental overdose</strong> – Massive accidental overdose with IT <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> must be treated vigorously since it can cause acute myelopathy, encephalopathy, and death. Patients with significant overdoses are treated with the combination of IT administration of <a class="drug drug_general" data-topicid="9048" href="/d/drug information/9048.html" rel="external">glucarpidase</a> (carboxypeptidase G2 [CPDG2]) to metabolize the methotrexate, and ventriculolumbar perfusion to reduce the amount of methotrexate in the CSF. The approach to such overdoses in discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Accidental overdose of intrathecal methotrexate'</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h3">Thiotepa</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9992" href="/d/drug information/9992.html" rel="external">Thiotepa</a> is highly lipid soluble, rapidly diffuses out of the CSF (within four hours), and has the shortest half-life of the agents used for IT chemotherapy.</p><p>The efficacy of IT <a class="drug drug_general" data-topicid="9992" href="/d/drug information/9992.html" rel="external">thiotepa</a> is not as well established as that of IT <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. In a multicenter randomized trial of IT thiotepa versus IT methotrexate in 59 patients with LMD, complete cytologic clearance was seen in approximately one-third of patients treated with each agent, and median survivals were similar (14 versus 16 weeks) [<a href="#rid2">2</a>]. A single-center retrospective study that included 66 breast cancer patients with LMD treated with IT thiotepa every two weeks reported similar results, with a cytologic response in 16 of 36 evaluable patients and a median overall survival of 4.5 months [<a href="#rid117">117</a>]. Another retrospective study of 24 patients with breast cancer who had failed liposomal cytarabine yielded a median progression-free survival of 3.1 months and an overall survival of 4.0 months, with minimal toxicity [<a href="#rid118">118</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The usual regimen of IT <a class="drug drug_general" data-topicid="9992" href="/d/drug information/9992.html" rel="external">thiotepa</a> is 10 mg IT on the same twice-weekly schedule as <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, with subsequent reductions in dose in responding patients [<a href="#rid2">2,119</a>], although less frequent dosing (eg, every two weeks) has also been reported [<a href="#rid117">117</a>]. Thiotepa has been used in patients who have failed methotrexate, have methotrexate-induced leukoencephalopathy, or need concurrent brain radiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – IT <a class="drug drug_general" data-topicid="9992" href="/d/drug information/9992.html" rel="external">thiotepa</a> tends to be well tolerated. Rare cases of myelopathy have been reported. It does have the potential to cause systemic myelosuppression [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H3866462376"><span class="h3">Cytarabine</span><span class="headingEndMark"> — </span>Conventional <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> is relatively ineffective in patients with LMD due to solid tumors, and its use is usually restricted to those with LMD from leukemia or lymphoma. The conventional formulation has a half-life of less than four hours in the CSF and is entirely eliminated within one to two days [<a href="#rid120">120,121</a>]. (See  <a class="medical medical_review" href="/d/html/4720.html" rel="external">"Secondary central nervous system lymphoma: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/4521.html" rel="external">"Involvement of the central nervous system (CNS) with acute myeloid leukemia (AML)"</a>.)</p><p>Liposomal cytarabine (DepoCyt), which had a longer half-life, was used in the past for LMD [<a href="#rid3">3,122-124</a>] but is no longer commercially available [<a href="#rid125">125</a>].</p><p class="headingAnchor" id="H2624250049"><span class="h3">Trastuzumab</span><span class="headingEndMark"> — </span>IT delivery of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> is an emerging option in patients with human epidermal growth factor receptor 2 (HER2)-positive cancers, particularly breast cancer. Overall, the evidence supports IT trastuzumab 80 mg twice weekly as a reasonable and well-tolerated IT therapy.</p><p>Multiple small series have demonstrated that 25 to 150 mg of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> in preservative-free <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> is well tolerated [<a href="#rid126">126-131</a>]. In the largest phase I/II multicenter study of 34 patients with HER2-positive cancers, only one grade 4 toxicity (arachnoiditis) was encountered at the 80 mg twice-weekly IT trastuzumab dose level [<a href="#rid132">132</a>]. Pharmacokinetic analysis suggested a CSF half-life of 4.1 hours after a single dose of 80 mg.</p><p>The phase II portion of the study included 23 patients with HER2-positive breast cancer LMD treated with 80 mg (twice weekly for the first four weeks, then weekly for four weeks, then every one to two weeks as maintenance) [<a href="#rid132">132</a>]. Rates of partial response, stable disease, and progressive disease were 19, 50, and 30 percent, respectively. With a median follow-up of 10.5 months, median progression-free and overall survival were 2.8 and 10.5 months, respectively (measured from study enrollment). Four patients received concomitant CNS-penetrating therapies (high-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> in one patient and <a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">lapatinib</a> in three patients).</p><p class="headingAnchor" id="H26"><span class="h3">Investigational intrathecal therapies</span><span class="headingEndMark"> — </span>The limited effectiveness of currently available agents for IT administration has led to the evaluation of several alternatives.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">Etoposide</a> – At least three reports have evaluated IT etoposide for LMD [<a href="#rid133">133-135</a>]. Treatment was well tolerated, but there are inadequate data to draw any conclusions regarding its relative efficacy. <a class="drug drug_general" data-topicid="10007" href="/d/drug information/10007.html" rel="external">Topotecan</a> is occasionally given IT and may be a reasonable second-line choice for solid tumors such as lung and ovarian [<a href="#rid136">136</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a> – A first-in-human study of IT pemetrexed plus IT <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> in patients with LMD due to epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) arrived at a phase II dose of 50 mg of pemetrexed given twice per week for the first week, then weekly for three weeks, then once monthly [<a href="#rid137">137</a>]. Myelosuppression was the most common side effect (37 percent), followed by nausea/vomiting and neurotoxicity (eg, limb pain, headache). Among 30 patients in the phase II study, median overall survival was nine months and clinical responses were reported in the majority of evaluable patients. These encouraging results suggest that further study is indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunotherapy</strong> – Administering concurrent IT and intravenous <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> has been evaluated in an initial clinical trial of patients with metastatic melanoma and LMD, but the approach remains investigational [<a href="#rid138">138</a>]. IT <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> is also under investigation in at least one trial [<a href="#rid139">139</a>].</p><p></p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy</strong> – Leptomeningeal disease (LMD) from solid tumors is usually a late-stage development associated with a prognosis of three to four months. Goals of treatment include stabilizing or improving neurologic function and palliating symptoms. Extended survival is occasionally achieved. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic assessment</strong> – Patients with a Karnofsky Performance Status (KPS) ≤60  (<a class="graphic graphic_table graphicRef58785" href="/d/graphic/58785.html" rel="external">table 2</a>); multiple, serious, fixed neurologic deficits; untreated, symptomatic hydrocephalus; and extensive systemic cancer with limited remaining therapeutic options have a poor prognosis even with active treatment.</p><p></p><p class="bulletIndent1">In the absence of these factors, the potential for sustained tumor control is most often signaled by the presence of reasonable remaining systemic treatment options, particularly ones with central nervous system (CNS) activity. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgent symptomatic interventions</strong> – For relatively good-risk patients with a cancer for which reasonable treatment options remain, treatment is directed at palliating symptomatic sites of disease with radiation therapy (RT) when possible, correcting structural problems such as hydrocephalus, and then attempting further CNS disease control with systemic or intrathecal (IT) therapy  (<a class="graphic graphic_algorithm graphicRef131588" href="/d/graphic/131588.html" rel="external">algorithm 1</a>) (see <a class="local">'Treatment plan and sequencing'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>RT to symptomatic sites </strong>– RT is used whenever possible to treat symptomatic areas of LMD, since systemic or IT therapy alone rarely reverses neurologic signs and symptoms. The most commonly used forms of RT for LMD are lumbosacral spine RT (for symptomatic cauda equina disease) and whole brain or skull base RT (for cranial neuropathies, diffuse encephalopathy, and mild hydrocephalus). (See <a class="local">'Involved field radiation'</a> above.)</p><p></p><p class="bulletIndent2">Craniospinal RT with <strong>photon</strong> radiation is<strong> </strong>typically<strong> </strong>not appropriate in patients with LMD from solid tumors due to high toxicity and short life expectancy. However, where available, <strong>proton</strong> craniospinal RT, which has an improved toxicity profile compared with photon craniospinal RT, is an option in selected patients with better prognosis and adequate functional status. (See <a class="local">'Proton craniospinal radiation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe hydrocephalus </strong>– Most patients with severe hydrocephalus from LMD require placement of a ventriculoperitoneal (VP) shunt before attempting further CNS-directed therapy. Patients with a poor prognosis are usually managed supportively without shunting, unless symptoms cannot be controlled with steroids, pain medications, and antiemetics. (See <a class="local">'Shunting versus radiation therapy'</a> above and <a class="local">'Ventriculoperitoneal shunting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Less severe hydrocephalus</strong> – Management of less severe forms of hydrocephalus and increased intracranial pressure (ICP) is individualized. Symptomatic glucocorticoids, shunting, and RT all play a role. The appropriate therapy depends on the severity of hydrocephalus and the type (communicating or noncommunicating), as described above. (See <a class="local">'Glucocorticoids'</a> above and <a class="local">'Shunting versus radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further CNS-directed therapy</strong> – Although local therapies are often indicated for palliation, LMD is a disseminated process, and further systemic or IT anticancer therapy with the ability to reach the full neuroaxis must be given if disease is to be controlled.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systemic therapy</strong> – For most patients with a systemic therapy option that has both efficacy against the primary tumor and a reasonable likelihood of CNS penetration or activity, we suggest systemic therapy rather than IT therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">There is no single drug with guaranteed activity across different histologies in patients with LMD. In general, we choose an agent (chemotherapy, targeted therapy, or immunotherapy) with the highest likelihood of both CNS penetration and efficacy against the primary cancer. (See <a class="local">'Systemic therapy options'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intrathecal therapy</strong> – For patients who do not have a good systemic therapy option but are nonetheless candidates for further CNS-directed therapy, we suggest IT chemotherapy via an Ommaya reservoir (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The best candidates for IT therapy are those without bulky LMD, with no hydrocephalus, and with no parenchymal brain metastases. (See <a class="local">'Intrathecal therapy'</a> above.)</p><p></p><p class="bulletIndent2">For most patients selected for IT therapy, we suggest IT <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). IT <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> is a reasonable alternative in patients with HER2-positive cancers. When placement of an Ommaya reservoir is difficult or impossible, systemic chemotherapy with high-dose methotrexate is an alternative to IT therapy in patients with breast cancer. (See <a class="local">'Methotrexate'</a> above and <a class="local">'Trastuzumab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Intensive supportive care is important and often essential to achieve acceptable quality of life in patients with LMD, regardless of goals of care. (See <a class="local">'Supportive care needs'</a> above.)</p><p></p><p class="bulletIndent1">For patients with a very poor prognosis who are not candidates for further tumor-directed therapy, glucocorticoids, pain medications, and antiseizure medications are used to control symptoms. RT directed to symptomatic sites of disease and even VP shunting may be necessary in selected patients for optimal symptom control. (See <a class="local">'Radiation to symptomatic sites'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5:1655.</a></li><li><a class="nounderline abstract_t">Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11:561.</a></li><li><a class="nounderline abstract_t">Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999; 5:3394.</a></li><li><a class="nounderline abstract_t">Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17:3110.</a></li><li><a class="nounderline abstract_t">Le Rhun E, Devos P, Weller J, et al. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro Oncol 2021; 23:1100.</a></li><li><a class="nounderline abstract_t">Morikawa A, Jordan L, Rozner R, et al. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clin Breast Cancer 2017; 17:23.</a></li><li><a class="nounderline abstract_t">Yang JCH, Kim SW, Kim DW, et al. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol 2020; 38:538.</a></li><li><a class="nounderline abstract_t">Ahn MJ, Chiu CH, Cheng Y, et al. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. J Thorac Oncol 2020; 15:637.</a></li><li><a class="nounderline abstract_t">Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015; 10:232.</a></li><li><a class="nounderline abstract_t">Li Z, Li P, Yan B, et al. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report. Thorac Cancer 2020; 11:176.</a></li><li><a class="nounderline abstract_t">Gaye E, Geier M, Bore P, et al. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis. Lung Cancer 2019; 133:1.</a></li><li><a class="nounderline abstract_t">Gainor JF, Chi AS, Logan J, et al. Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. J Thorac Oncol 2016; 11:256.</a></li><li><a class="nounderline abstract_t">Zima LA, Tulpule S, Samson K, Shonka N. Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease. J Neurol Sci 2019; 403:19.</a></li><li><a class="nounderline abstract_t">Adil SM, Hodges SE, Edwards RM, et al. Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States. Neurooncol Pract 2020; 7:636.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers https://www.nccn.org/professionals/physician_gls/default.aspx#site (Accessed on March 09, 2021).</li><li><a class="nounderline abstract_t">Le Rhun E, Weller M, Brandsma D, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 2017; 28:iv84.</a></li><li><a class="nounderline abstract_t">Le Rhun E, Preusser M, van den Bent M, et al. How we treat patients with leptomeningeal metastases. ESMO Open 2019; 4:e000507.</a></li><li><a class="nounderline abstract_t">Yan W, Liu Y, Li J, et al. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis. Radiat Oncol 2019; 14:168.</a></li><li><a class="nounderline abstract_t">Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012; 7:382.</a></li><li><a class="nounderline abstract_t">Zhen J, Wen L, Lai M, et al. Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiat Oncol 2020; 15:185.</a></li><li><a class="nounderline abstract_t">Yang TJ, Wijetunga NA, Yamada J, et al. Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro Oncol 2021; 23:134.</a></li><li><a class="nounderline abstract_t">Yang JT, Wijetunga NA, Pentsova E, et al. Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. J Clin Oncol 2022; 40:3858.</a></li><li><a class="nounderline abstract_t">Chamberlain MC, Kormanik P, Jaeckle KA, Glantz M. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1999; 52:216.</a></li><li><a class="nounderline abstract_t">Kim HS, Park JB, Gwak HS, et al. Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis. World J Surg Oncol 2019; 17:59.</a></li><li><a class="nounderline abstract_t">Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005; 64:1625.</a></li><li><a class="nounderline abstract_t">Lamba N, Fick T, Nandoe Tewarie R, Broekman ML. Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making. J Neurooncol 2018; 140:5.</a></li><li><a class="nounderline abstract_t">Lee SH, Kong DS, Seol HJ, et al. Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis. J Neurooncol 2011; 104:545.</a></li><li><a class="nounderline abstract_t">Bander ED, Yuan M, Reiner AS, et al. Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes. J Neurooncol 2021; 154:301.</a></li><li><a class="nounderline abstract_t">Lu VM, Abou-Al-Shaar H, Bin-Alamer O, et al. Postoperative course of cerebrospinal fluid diversion in the setting of leptomeningeal disease: a systematic review, meta-analysis, and meta-regression with an illustrative case. J Neurooncol 2023; 163:29.</a></li><li><a class="nounderline abstract_t">Dhaliwal J, Ruiz-Perez M, Mihaela-Vasilica A, et al. Survival and quality of life after CSF diversion in adult patients with leptomeningeal metastasis-associated hydrocephalus: a systematic review and meta-analysis. Neurosurg Focus 2023; 55:E16.</a></li><li><a class="nounderline abstract_t">Piatt JH Jr, Garton HJ. Clinical diagnosis of ventriculoperitoneal shunt failure among children with hydrocephalus. Pediatr Emerg Care 2008; 24:201.</a></li><li><a class="nounderline abstract_t">Kay MD, Pariury HE, Perry A, et al. Extracranial Metastases From Glioblastoma With Primitive Neuronal Components on FDG PET/CT. Clin Nucl Med 2020; 45:e162.</a></li><li><a class="nounderline abstract_t">Ng JJ, Teo KA, Shabbir A, Yeo TT. Widespread Intra-abdominal Carcinomatosis from a Rhabdoid Meningioma after Placement of a Ventriculoperitoneal Shunt: A Case Report and Review of the Literature. Asian J Neurosurg 2018; 13:386.</a></li><li><a class="nounderline abstract_t">Burger MC, Wagner M, Franz K, et al. Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases. J Clin Med 2018; 7.</a></li><li><a class="nounderline abstract_t">Lin N, Dunn IF, Glantz M, et al. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg 2011; 115:730.</a></li><li><a class="nounderline abstract_t">Moss NS, Singh JM, Reiner AS, et al. Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis. NPJ Breast Cancer 2023; 9:86.</a></li><li><a class="nounderline abstract_t">Pérez-García JM, Vaz Batista M, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol 2023; 25:157.</a></li><li><a class="nounderline abstract_t">Niikura N, Yamanaka T, Nomura H, et al. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM). NPJ Breast Cancer 2023; 9:82.</a></li><li><a class="nounderline abstract_t">Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 1998; 16:1561.</a></li><li><a class="nounderline abstract_t">Bazan F, Dobi E, Royer B, et al. Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer. BMC Cancer 2019; 19:1029.</a></li><li><a class="nounderline abstract_t">Lassman AB, Abrey LE, Shah GD, et al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006; 78:255.</a></li><li><a class="nounderline abstract_t">Kapke JT, Schneidewend RJ, Jawa ZA, et al. High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature. Hematol Oncol Stem Cell Ther 2019; 12:189.</a></li><li><a class="nounderline abstract_t">Santa-Maria CA, Cimino-Mathews A, Moseley KF, et al. Complete radiologic response and long-term survival with use of systemic high-dose methotrexate for breast cancer-associated leptomeningeal disease. Clin Breast Cancer 2012; 12:445.</a></li><li><a class="nounderline abstract_t">Tetef ML, Margolin KA, Doroshow JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 2000; 46:19.</a></li><li><a class="nounderline abstract_t">Bernard S, Hachon L, Diasonama JF, et al. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma. Ann Hematol 2021; 100:979.</a></li><li><a class="nounderline abstract_t">Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 2003; 65:167.</a></li><li><a class="nounderline abstract_t">Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro Oncol 2004; 6:63.</a></li><li><a class="nounderline abstract_t">Shigekawa T, Takeuchi H, Misumi M, et al. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 2009; 16:88.</a></li><li><a class="nounderline abstract_t">Ekenel M, Hormigo AM, Peak S, et al. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007; 85:223.</a></li><li><a class="nounderline abstract_t">Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 2006; 7:164.</a></li><li><a class="nounderline abstract_t">Vincent A, Lesser G, Brown D, et al. Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. J Breast Cancer 2013; 16:122.</a></li><li><a class="nounderline abstract_t">McLean LS, Faisal W, Parakh S, et al. Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. JCO Precis Oncol 2021; 5:561.</a></li><li><a class="nounderline abstract_t">Tamiya A, Tamiya M, Nishihara T, et al. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study. Anticancer Res 2017; 37:4177.</a></li><li><a class="nounderline abstract_t">Hochmair M. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. Target Oncol 2018; 13:269.</a></li><li><a class="nounderline abstract_t">Ma C, Wang S, Mu N, et al. Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report. Front Oncol 2020; 10:1635.</a></li><li><a class="nounderline abstract_t">Liu J, Jin B, Su H, et al. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report. BMC Cancer 2019; 19:702.</a></li><li><a class="nounderline abstract_t">Kanaji N, Bandoh S, Nagamura N, et al. Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. Intern Med 2007; 46:1651.</a></li><li><a class="nounderline abstract_t">Sakai M, Ishikawa S, Ito H, et al. Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol 2006; 11:243.</a></li><li><a class="nounderline abstract_t">Hashimoto N, Imaizumi K, Honda T, et al. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer 2006; 53:387.</a></li><li><a class="nounderline abstract_t">So T, Inoue M, Chikaishi Y, et al. Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases. Surg Today 2009; 39:598.</a></li><li><a class="nounderline abstract_t">Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009; 65:80.</a></li><li><a class="nounderline abstract_t">Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006; 24:4517.</a></li><li><a class="nounderline abstract_t">Dhruva N, Socinski MA. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 2009; 27:e31.</a></li><li><a class="nounderline abstract_t">Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010; 99:283.</a></li><li><a class="nounderline abstract_t">Cessot A, Blanchet B, Goldwasser F. Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better. Ann Oncol 2014; 25:2093.</a></li><li><a class="nounderline abstract_t">Kawamura T, Hata A, Takeshita J, et al. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs. Cancer Chemother Pharmacol 2015; 75:1261.</a></li><li><a class="nounderline abstract_t">Kashima J, Okuma Y, Miwa M, Hosomi Y. Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib. Jpn J Clin Oncol 2017; 47:357.</a></li><li><a class="nounderline abstract_t">Flippot R, Biondani P, Auclin E, et al. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. J Thorac Oncol 2019; 14:1400.</a></li><li><a class="nounderline abstract_t">Bauer TM, Shaw AT, Johnson ML, et al. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Target Oncol 2020; 15:55.</a></li><li><a class="nounderline abstract_t">Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014; 15:1119.</a></li><li><a class="nounderline abstract_t">Ou SH, Sommers KR, Azada MC, Garon EB. Alectinib induces a durable (&gt;15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 2015; 20:224.</a></li><li><a class="nounderline abstract_t">Camidge DR, Kim DW, Tiseo M, et al. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol 2018; 36:2693.</a></li><li><a class="nounderline abstract_t">Huber RM, Hansen KH, Paz-Ares Rodríguez L, et al. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol 2020; 15:404.</a></li><li><a class="nounderline abstract_t">Costa DB, Shaw AT, Ou SH, et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol 2015; 33:1881.</a></li><li><a class="nounderline abstract_t">Chorti E, Kebir S, Ahmed MS, et al. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities. Eur J Cancer 2021; 148:395.</a></li><li><a class="nounderline abstract_t">Bander ED, Yuan M, Carnevale JA, et al. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. Cancer 2021; 127:2062.</a></li><li><a class="nounderline abstract_t">Schäfer N, Scheffler B, Stuplich M, et al. Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 2013; 31:e173.</a></li><li><a class="nounderline abstract_t">Lee JM, Mehta UN, Dsouza LH, et al. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res 2013; 23:175.</a></li><li><a class="nounderline abstract_t">Floudas CS, Chandra AB, Xu Y. Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival. Melanoma Res 2016; 26:312.</a></li><li><a class="nounderline abstract_t">Kim DW, Barcena E, Mehta UN, et al. Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer 2015; 15:400.</a></li><li><a class="nounderline abstract_t">Wilgenhof S, Neyns B. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib. J Clin Oncol 2015; 33:e109.</a></li><li><a class="nounderline abstract_t">Simeone E, De Maio E, Sandomenico F, et al. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep 2012; 6:131.</a></li><li><a class="nounderline abstract_t">Geukes Foppen MH, Brandsma D, Blank CU, et al. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann Oncol 2016; 27:1138.</a></li><li><a class="nounderline abstract_t">Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018; 19:672.</a></li><li><a class="nounderline abstract_t">Bot I, Blank CU, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 2012; 259:1976.</a></li><li><a class="nounderline abstract_t">Glitza IC, Ferguson SD, Guha-Thakurta N. Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient. J Neurooncol 2017; 133:663.</a></li><li><a class="nounderline abstract_t">Ferguson SD, Bindal S, Bassett RL Jr, et al. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol 2019; 142:499.</a></li><li><a class="nounderline abstract_t">Dietrich C, Salzmann M, Steinbrecher A, et al. Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab. Immunotherapy 2021; 13:1079.</a></li><li><a class="nounderline abstract_t">Wu RC, Newman W, Patanowitz L, et al. Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient. Immunotherapy 2020; 12:763.</a></li><li><a class="nounderline abstract_t">Misir Krpan A, Rakusic Z, Herceg D. Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report. Medicine (Baltimore) 2020; 99:e22928.</a></li><li><a class="nounderline abstract_t">Palacka P, Slopovsky J, Makovnik M, et al. A case report of a patient with inoperable primary diffuse leptomeningeal melanomatosis treated with whole-brain radiotherapy and pembrolizumab. Medicine (Baltimore) 2022; 101:e28613.</a></li><li><a class="nounderline abstract_t">Johnson WR, Theeler BJ, Van Echo D, et al. Treatment of Leptomeningeal Carcinomatosis in a Patient with Metastatic Pancreatic Cancer: A Case Report and Review of the Literature. Case Rep Oncol 2018; 11:281.</a></li><li><a class="nounderline abstract_t">Kiewe P, Thiel E, Reinwald M, Korfel A. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors. J Neurooncol 2011; 103:629.</a></li><li><a class="nounderline abstract_t">Nandipati S, Demopoulos A. Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide. J Neurooncol 2011; 105:663.</a></li><li><a class="nounderline abstract_t">Palmisciano P, Haider AS, Nwagwu CD, et al. The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review. Anticancer Res 2021; 41:5333.</a></li><li><a class="nounderline abstract_t">Arias Ron D, Labandeira CM, Areses Manrique MC, et al. Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report. Front Oncol 2019; 9:819.</a></li><li><a class="nounderline abstract_t">Bover M, Yarza R, Docampo LI. Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non-Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm. Clin Lung Cancer 2020; 21:e1.</a></li><li><a class="nounderline abstract_t">Bonomi L, Bettini AC, Arnoldi E, et al. Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: a case report. Tumori 2020; 106:NP76.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Lee EQ, Cohen JV, et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med 2020; 26:1280.</a></li><li><a class="nounderline abstract_t">Brastianos PK, Strickland MR, Lee EQ, et al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun 2021; 12:5954.</a></li><li><a class="nounderline abstract_t">Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004; 40:2726.</a></li><li><a class="nounderline abstract_t">Grossman SA, Reinhard CS, Loats HL. The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurooncol 1989; 7:319.</a></li><li><a class="nounderline abstract_t">Burch PA, Grossman SA, Reinhard CS. Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study. J Natl Cancer Inst 1988; 80:1211.</a></li><li><a class="nounderline abstract_t">Grossman SA, Trump DL, Chen DC, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 1982; 73:641.</a></li><li><a class="nounderline abstract_t">Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology 1991; 41:1765.</a></li><li><a class="nounderline abstract_t">Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995; 75:2919.</a></li><li><a class="nounderline abstract_t">Shapiro WR, Young DF, Mehta BM. Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293:161.</a></li><li><a class="nounderline abstract_t">Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 2010; 116:1947.</a></li><li><a class="nounderline abstract_t">Zairi F, Le Rhun E, Bertrand N, et al. Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. J Neurooncol 2015; 124:317.</a></li><li><a class="nounderline abstract_t">Sandberg DI, Bilsky MH, Souweidane MM, et al. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000; 47:49.</a></li><li><a class="nounderline abstract_t">Sullivan MP, Moon TE, Trueworthy R, et al. Combination intrathecal therapy for meningeal leukemia: two versus three drugs. Blood 1977; 50:471.</a></li><li><a class="nounderline abstract_t">Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: Analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44:1463.</a></li><li><a class="nounderline abstract_t">Pfeffer MR, Wygoda M, Siegal T. Leptomeningeal metastases--treatment results in 98 consecutive patients. Isr J Med Sci 1988; 24:611.</a></li><li><a class="nounderline abstract_t">Sause WT, Crowley J, Eyre HJ, et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases--a Southwest Oncology Group study. J Neurooncol 1988; 6:107.</a></li><li><a class="nounderline abstract_t">Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982; 49:759.</a></li><li><a class="nounderline abstract_t">Rubin R, Owens E, Rall D. Transport of methotrexate by the choroid plexus. Cancer Res 1968; 28:689.</a></li><li><a class="nounderline abstract_t">Comte A, Jdid W, Guilhaume MN, et al. Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neurooncol 2013; 115:445.</a></li><li><a class="nounderline abstract_t">Le Rhun E, Taillibert S, Devos P, et al. Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases: a retrospective case series. Anticancer Drugs 2013; 24:1093.</a></li><li><a class="nounderline abstract_t">Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 1977; 61:885.</a></li><li><a class="nounderline abstract_t">Fulton DS, Levin VA, Gutin PH, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 1982; 8:285.</a></li><li><a class="nounderline abstract_t">Esteva FJ, Soh LT, Holmes FA, et al. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 2000; 46:382.</a></li><li><a class="nounderline abstract_t">Cole BF, Glantz MJ, Jaeckle KA, et al. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003; 97:3053.</a></li><li><a class="nounderline abstract_t">Jaeckle KA, Phuphanich S, Bent MJ, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001; 84:157.</a></li><li><a class="nounderline abstract_t">Fusco JP, Castañón E, Carranza OE, et al. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study. J Neurooncol 2013; 115:429.</a></li><li class="breakAll">Current drug shortages. American Society of Health-System Pharmacists. Available at: https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1298 (Accessed on January 29, 2018).</li><li><a class="nounderline abstract_t">Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2001; 2:235.</a></li><li><a class="nounderline abstract_t">Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006; 15:1373.</a></li><li><a class="nounderline abstract_t">Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006; 7:778.</a></li><li><a class="nounderline abstract_t">Stemmler HJ, Mengele K, Schmitt M, et al. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 2008; 19:832.</a></li><li><a class="nounderline abstract_t">Oliveira M, Braga S, Passos-Coelho JL, et al. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 2011; 127:841.</a></li><li><a class="nounderline abstract_t">Zagouri F, Sergentanis TN, Bartsch R, et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat 2013; 139:13.</a></li><li><a class="nounderline abstract_t">Kumthekar PU, Avram MJ, Lassman AB, et al. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol 2023; 25:557.</a></li><li><a class="nounderline abstract_t">Slavc I, Schuller E, Falger J, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol 2003; 64:239.</a></li><li><a class="nounderline abstract_t">Fleischhack G, Reif S, Hasan C, et al. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer 2001; 84:1453.</a></li><li><a class="nounderline abstract_t">Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 2006; 106:2021.</a></li><li><a class="nounderline abstract_t">Groves MD, Glantz MJ, Chamberlain MC, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 2008; 10:208.</a></li><li><a class="nounderline abstract_t">Fan C, Zhao Q, Li L, et al. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615). J Thorac Oncol 2021; 16:1359.</a></li><li><a class="nounderline abstract_t">Glitza Oliva IC, Ferguson SD, Bassett R Jr, et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 2023; 29:898.</a></li><li class="breakAll">ClinicalTrials.gov (NCT05598853): https://clinicaltrials.gov/ct2/show/NCT05598853.</li></ol></div><div id="topicVersionRevision">Topic 5184 Version 60.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3309199" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8445432" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589750" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506606" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33367859" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27569275" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31809241" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31887431" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25526238" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31766077" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31200813" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26845119" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31176194" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33312678" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33312678" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28881917" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31231573" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : How we treat patients with leptomeningeal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31521171" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22089116" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32736566" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32592583" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical trial of proton craniospinal irradiation for leptomeningeal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35802849" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9921888" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30917830" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883329" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ventriculoperitoneal shunt in patients with leptomeningeal metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30022283" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21274592" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34406564" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37191912" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Postoperative course of cerebrospinal fluid diversion in the setting of leptomeningeal disease: a systematic review, meta-analysis, and meta-regression with an illustrative case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37527677" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Survival and quality of life after CSF diversion in adult patients with leptomeningeal metastasis-associated hydrocephalus: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18431216" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical diagnosis of ventriculoperitoneal shunt failure among children with hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31876829" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Extracranial Metastases From Glioblastoma With Primitive Neuronal Components on FDG PET/CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29682040" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Widespread Intra-abdominal Carcinomatosis from a Rhabdoid Meningioma after Placement of a Ventriculoperitoneal Shunt: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30110924" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21721878" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37867174" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35639825" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37821514" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552066" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31675937" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344918" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Systemic high-dose intravenous methotrexate for central nervous system metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31629723" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23010203" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Complete radiologic response and long-term survival with use of systemic high-dose methotrexate for breast cancer-associated leptomeningeal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10912573" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33608849" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14686737" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Response of neoplastic meningitis from solid tumors to oral capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769142" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18478315" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17611719" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Capecitabine therapy of central nervous system metastases from breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16800978" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23593093" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34994604" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28739703" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29700687" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33014823" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31315676" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17917328" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16850132" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16824645" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19562448" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19059670" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16983123" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487379" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20146086" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25057169" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25921002" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28064206" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31108248" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32060867" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25153538" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25568147" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Alectinib induces a durable (&gt;15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768119" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31756496" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25624436" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33789203" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33651913" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460716" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Vemurafenib for leptomeningeal melanomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23358426" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26974967" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25962795" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733801" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22594466" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26961150" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29602646" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22527228" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528423" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30847840" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34259028" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32571131" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33327228" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35060532" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A case report of a patient with inoperable primary diffuse leptomeningeal melanomatosis treated with whole-brain radiotherapy and pembrolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29867436" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Treatment of Leptomeningeal Carcinomatosis in a Patient with Metastatic Pancreatic Cancer: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20941526" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21626072" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34732403" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31552167" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31601524" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Four-Year Lasting Sustained Complete Response After Nivolumab in a Patient With Non-Small-Cell Lung Cancer and Confirmed Leptomeningeal Carcinomatosis: Changing the Paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32041500" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32483359" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34642329" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15571954" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2585028" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3418727" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6814249" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944906" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Leptomeningeal metastases: 111indium-DTPA CSF flow studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7773943" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/806016" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20151421" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070555" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10917346" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Ommaya reservoirs for the treatment of leptomeningeal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/577889" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Combination intrathecal therapy for meningeal leukemia: two versus three drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8058150" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3144516" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Leptomeningeal metastases--treatment results in 98 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3225633" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases--a Southwest Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6895713" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5649058" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Transport of methotrexate by the choroid plexus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24043602" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23962903" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases: a retrospective case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/408003" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6897022" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127942" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12784341" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11161370" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037499" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037499" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11899418" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16596213" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16945774" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18690096" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21369716" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23588955" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35948282" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14558599" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384092" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16583432" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316473" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33989780" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36997799" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
